Discovery of novel biomarkers in peripheral arterial disease/metabolic syndrome

Trial Profile

Discovery of novel biomarkers in peripheral arterial disease/metabolic syndrome

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Peripheral arterial disorders; Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Acronyms PAD Wyeth
  • Most Recent Events

    • 16 Mar 2012 Actual end date (19 Dec 2008) added as reported by EudraCT.
    • 17 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top